Cold agglutinin disease by NovelMed Therapeutics for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cold agglutinin disease overview
The therapeutic candidate is under development for the treatment of cold agglutinin disease.
NovelMed Therapeutics overview
NovelMed Therapeutics (NovelMed) is a biotechnology company. The company develops transformative therapies for the treatment of orphan and non-orphan diseases. It offers monoclonal antibodies in the therapeutic areas of paroxysmal nocturnal hemoglobinuria, age related macular degeneration, osteoarthritis, ischemia, arthritis and chronic kidney diseases, among others. NovelMed also provides Inflammin, a cardiovascular device that converts the blood into a form that resists AP activation during cardiac procedures. It also conducts research and development for complement-mediated diseases. The company caters to patients, healthcare providers, employees, and investors across the US. NovelMed is headquartered in Cleveland, Ohio, the US.
For a complete picture of Cold agglutinin disease’s drug-specific PTSR and LoA scores, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Source link
#Cold #agglutinin #disease #NovelMed #Therapeutics #Acquired #Autoimmune #Hemolytic #Anemia #Likelihood #Approval
